Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Angel D who wrote (889)	4/30/1998 6:36:00 PM
From: Saul H Rosenthal	Respond to of 1432

If you stop and think about it there is no way Abbott would have bothered to get involved if the market was only $30 million or even $100 million. I mean really , would Abbott have spent 4 months negotiating the details of a contract with BTIM if the market was $30 million. If you really think about that $30 million claim by Ascensio you will realize how ridiculous it is. Abbott has also taken an option to take BTIM's second product as well. If you believe Ascensio's estimate of the market you have to believe that he understands the medical market better than Abbott, which I really doubt. If you also realize that the FDA let BTIM go straight to phase 3, which is very unusual, because the FDA is anxious to get this product on the market because of concerns about the blood supply -- and that the FDA also worked out the sequence of testing with BTIM, and the design of the study, before BTIM's start of their phase 3 study -- you wont be fooled or scared out of this potentially blockbuster stock. Saul